BeOne Medicines (BEIGF) EBITDA Margin Growth (3y) (2018 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) EBITDA Margin Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | 842.00 |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 214.00 |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -963.00 |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 2,139.00 |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | -1,031.00 |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 7,261.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,261.00 |
| Mar 31, 2026 | 9,942.00 |
| Dec 31, 2025 | 13,564.00 |
| Sep 30, 2025 | 12,464.00 |
| Jun 30, 2025 | 13,532.00 |
| Mar 31, 2025 | 14,556.00 |
| Dec 31, 2024 | 26,015.00 |
| Sep 30, 2024 | 21,194.00 |
| Jun 30, 2024 | 30,504.00 |
| Mar 31, 2024 | -4,635.00 |
| Dec 31, 2023 | 42,393.00 |
| Sep 30, 2023 | 46,610.00 |
| Jun 30, 2023 | 49,323.00 |
| Mar 31, 2023 | 63,504.00 |
| Dec 31, 2022 | 55,877.00 |
| Sep 30, 2022 | 50,969.00 |
| Jun 30, 2022 | -9,337.00 |
| Mar 31, 2022 | 7,867.00 |
| Dec 31, 2021 | 21,143.00 |
| Sep 30, 2021 | 5,482.00 |